In 2024, Life Chemicals brought into active use 12 novel Screening Libraries and 9 assay-ready freshly Pre-plated Focused Libraries to facilitate time- and cost-efficiency of drug discovery. For your convenience, these Libraries are briefly summarized below.
|
1,100 predicted selective Kir6.1/SUR2B inhibitors applicable to drug discovery focused on cardiovascular disease.
|
|
|
6,200 autophagy-associated screening compounds, including predicted inhibitors of mTOR and PI3K, apoptosis regulators, ROS and AMPK modulators, and other relevant protease and kinase inhibitors, making it ideal for studying autophagy pathways. |
|
|
1,200 drug-like screening compounds predicted to target protein-glutamine gamma-glutamyltransferase 2 (TG2), a critical enzyme involved in gliadin peptide modification, a key mechanism in celiac disease pathogenesis. |
|
|
over 75,000 unique and diverse screening compounds selected by means of the Bemis-Murcko scaffolding approach, enabling exploration of a broader chemical space with distinct core structures. |
|
|
5,500 drug-like screening compounds with predicted dehydrogenase activity, picked out by advanced ligand- and receptor-based methods for exploration of metabolic enzyme modulation. |
|
|
developed in collaboration with Variational AI, this library includes 2,500 drug-like compounds with predicted inhibitory activity at the ATP site of EGFR, a relevant target for cancer therapy. |
|
|
more than 5,000 screening compounds bearing diverse lysine-focused electrophilic warheads to target lysine residues in proteins for advanced covalent drug discovery. |
|
|
featuring over 250 mectin-like molecules in stock and supported by in-house expertise for synthesizing customizable analogs for potential applications as insecticides, acaricides and antiviral agents, convertible into monoglycosides and aglycones. |
|
|
900 drug-like screening compounds identified via molecular docking to exhibit inhibitory activity against nicotinic acetylcholine receptors to advance neurological and therapeutic research. |
|
|
1,500 drug-like compounds with predicted inhibitory activity against T-cell immunoglobulin and mucin domain 3 (TIM-3), contributing to research in immunotherapy and oncology. |
|
|
1,900 potential covalent modulators designed to covalently bind to tyrosine residues in target proteins, giving unique opportunities for therapeutic development. |
|
|
2,500 drug-like compounds with potential selectivity for zinc nuclear finger proteins, identified by ligand- and receptor-based screening approaches, aiding in epigenetic and transcriptional regulation research. |
Key advantages of these assay-ready libraries consist in the unparalleled flexibility of their set-based structures:
|
four non-overlapping sets of structurally diverse compounds, amounting to 8,640, 6,400, 4,245, and 3,520 3D-like molecules. |
|
|
7,360 drug-like screening compounds with predicted antiviral activity, available in subsets of 4,160 and 3,200 molecules. |
|
|
8,260 compounds containing chelating groups, split into subsets of 4,420, 2,560, and 1,280 agents. |
|
|
4,800 diverse covalent inhibitors featuring various warheads. |
|
|
6,080 small-molecule compounds with helicase-related activity, organized as subsets of 3,520 and 2,560. |
|
|
1,280 fragments with assured solubility (200 mM) in DMSO-d6, ready for NMR-based FBDD research. |
|
|
3,200 compounds targeting key kinases involved in cancer and inflammation. |
|
|
5,760 α-helix and β-turn mimetics selected through ligand-based approaches. |
|
|
6,400 structurally dissimilar compounds targeting protein-protein interactions. |
Your Big Breakthrough Can Start Immediately!
Make the most of our innovative screening libraries to powerfully drive your drug discovery journey with our intelligent molecules from the latest catalog. Contact us at marketing@lifechemicals.com to address your needs and any inquiries.